Follow us
Business News

Verano Holdings Foresees Uplisting Opportunities for Cannabis Companies

Verano Holdings Foresees Uplisting Opportunities for Cannabis Companies Nasdaq
Written by PsychePen

Prediction: current classification review will give publicly traded U.S. marijuana companies the chance to uplist to major stock exchanges.

Summary: Verano Holdings Corp. CEO, George Archos, anticipates that the ongoing classification review by the Biden administration will enable publicly traded U.S. marijuana companies to uplist to major stock exchanges through at least a rescheduling of the drug.

Follow Cannadelics:

Keep yourself informed with the latest from cannabis and psychedelics

U.S. Cannabis Companies Might Uplist to Major Exchanges, Predicts Verano Holdings CEO

Verano Holdings Corp. CEO, George Archos, expressed confidence during the company’s Q2 earnings call that the current classification review by the Biden administration will provide publicly traded U.S. marijuana companies the opportunity to uplist to major stock exchanges by at least rescheduling the drug. Archos highlighted that Verano is a member of the U.S. Cannabis Council, which has been lobbying the Biden administration on this issue since the review began last year.

Can we expect a change from Biden?

He stated, “With a rescheduling or descheduling status still on the horizon, we will continue our involvement at the federal level to help push progress forward. We ultimately anticipate that some form of federal action will create large changes for the industry, including the possibility of an uplisting to U.S. exchanges.

Uplisting to major exchanges like the New York Stock Exchange or the Nasdaq could significantly benefit many public companies in the cannabis industry by providing them access to more capital. This would be particularly beneficial for companies like Verano. Despite the company reporting positive business conditions and revising its financial guidance for the year to increase free cash flow projections to $65 million-$75 million, it still has a tax liability of $227 million, as noted by CFO Brett Summerer.

And Tilray is heavily investing in Craft Beer

However, some state-level tax credits, designed to alleviate the burden from the 280E provision in the federal tax code (which prevents cannabis companies from claiming standard business tax deductions), offset this debt. Archos mentioned that 280E offsets introduced in states like Connecticut, Illinois, and New Jersey have already saved Verano millions. He commented on the tax debts, stating, “We’re down from about $250 million to about $225 million. The state portion is a healthy portion, but not all of that, and that’s essentially a direct result of the 280E rollbacks that we saw in Illinois and New Jersey.”

With the increased free cash flow, the company is contemplating whether to continue paying down its tax debts, settle some of the debts it owes to Chicago Atlantic, or perhaps invest in expansion. Archos concluded by saying, “All options are on the table.”

[Source: Green Market Report]
Paying your taxes is only an option

Subscribe to our newsletter

We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!

Simply place your email below:



AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.

Is hemp-derived THC ban legal?

Have anything to add? Your voice matters! Join the conversation and contribute your insights and ideas below.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About the author


PsychePen is Cannadelics' main news editor. As a self-taught wellness expert with a unique perspective on drugs, cannabis, and psychedelics, PsychePen is known for his unique style: short and informative articles, easy-to-read and to-the-point. PsychePen is also one of our most successful AI authors. so its keep on improving.